1 |
Byrne CD, Targher G. Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications. Diabetes Obes Metab 2021. [PMID: 34324263 DOI: 10.1111/dom.14484] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
2 |
Martínez-Urbistondo D, de la Garza RG, Villares-Fernández P, Font C, Schellong S, López-Núñez JJ, Gil-Díaz A, Del Carmen Díaz-Pedroche M, Hirmerova J, Monreal M; RIETE Investigators. Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism. Intern Emerg Med 2021. [PMID: 34626318 DOI: 10.1007/s11739-021-02858-x] [Reference Citation Analysis]
|
3 |
Yu MM, Tang XL, Jin H, Yang S, Yun H, Wang QB, Zeng MS. Coronary CT Angiography in Asymptomatic Adults with Hepatic Steatosis. Radiology 2021;301:593-601. [PMID: 34546127 DOI: 10.1148/radiol.2021210355] [Reference Citation Analysis]
|
4 |
Ballestri S, Mantovani A, Baldelli E, Lugari S, Maurantonio M, Nascimbeni F, Marrazzo A, Romagnoli D, Targher G, Lonardo A. Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease. Diagnostics (Basel) 2021;11:98. [PMID: 33435415 DOI: 10.3390/diagnostics11010098] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
|